Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362318 | 0.87 | PKM (0.33) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL2363178 | 0.85 | PKM (0.40) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL18382969 | 0.83 | KDM4E (0.41) | KMT2ASMN1; SMN2POLBALDH1A1KDM4E | |
| SCHEMBL8551900 | 0.83 | KDM4E (0.44) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL16626084 | 0.80 | PKM (0.50) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL13365015 | 0.76 | KDM4E (0.47) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL4197869 | 0.74 | CYP1A2 (0.46) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL5092253 | 0.74 | SMN1; SMN2 (0.46) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL3062142 | 0.74 | MEN1 (0.56) | MEN1KMT2ASMN1; SMN2PKMNPC1 | |
| SCHEMBL8304642 | 0.74 | KDM4E (0.43) | MEN1KMT2ASMN1; SMN2PKMNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | MEN1 1220/4885KMT2A 1177/4885SMN1; SMN2 1979/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | MEN1 1334/4885KMT2A 1127/4885SMN1; SMN2 2492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.